Table 3.
Variables | 30 days (177 patients) | 30 days (first 53 cases) | 30 days (last 124 cases) |
---|---|---|---|
Death, n (%) | 5 (2.8%) | 2 (3.8%) | 3 (2.4%) |
Cardiovascular | 2 (1.1%) | 1 (1.9%) | 1 (0.8%) |
Non-cardiovascular | 3 (1.7%) | 1 (1.9%) | 2 (1.6%) |
Stroke, n (%) | 4 (2.3%) | 2 (3.8%) | 2 (1.6%) |
AMI, n (%) | 0 | 0 | 0 |
Major vascular complications, n (%) | 18 (10.2%) | 6 (11.3%) | 12 (9.7%) |
Life-threatening bleeding, n (%) | 6 (3.4%) | 2 (3.8%) | 4 (3.2%) |
AKI, n (%) | 9 (5.1%) | 3 (5.7%) | 6 (4.8%) |
Stage 1 | 7 (4%) | 3 (6.1%) | 4 (3.2%) |
Stage 2 or 3 | 2 (1.1%) | 0 | 2 (1.6%) |
PPM post-TAVI, n (%) | 14 (7.9%) | 2 (3.8%) | 12 (9.7%) |
30-day safety end point, n (%) | 24 (13.6%) | 8 (15.1%) | 16 (12.9%) |
AKI, acute kidney insufficiency; AMI, acute myocardial infarction; PPM, permanent pacemaker; RBC, red blood cell units; TAVI, transcatheter aortic valve implantation.